Should You Buy Zentalis Pharmaceuticals Inc (ZNTL) Stock on Monday?

Overall market sentiment has been high on Zentalis Pharmaceuticals Inc (ZNTL) stock lately. ZNTL receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Zentalis Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ZNTL!

See Full ZNTL Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With ZNTL Stock Today?

Zentalis Pharmaceuticals Inc (ZNTL) stock is trading at $12.85 as of 1:33 PM on Monday, Nov 6, a drop of -$5.03, or -28.13% from the previous closing price of $17.88. The stock has traded between $12.80 and $18.24 so far today. Volume today is more active than usual. So far 2,012,190 shares have traded compared to average volume of 883,411 shares.

More About Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer. Click Here to get the full Stock Report for Zentalis Pharmaceuticals Inc stock.